Category: Market Access
PharmaSignal — Market Access
Jazz and Lilly cancer drugs cleared for use by NHS
Pharmaphorum
Jazz’s biliary tract cancer drug Ziihera and Lilly’s Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
Pharmaceutical Technology
Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.
Multiple myeloma drug Blenrep backed for wider NHS use
Pharmaphorum
The revitalisation of GSK’s Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update
Drug Channels
It’s time for Drug Channels Institute’s (DCI) annual update of vertical integration among insurers, PBMs, specialty pharmacies, and healthcare services within U.S.
Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update
KFF Medicare
The Trump administration this week backed off a key element of its Medicare Advantage rate proposal, resulting in billions of dollars in additional payments to private insurers.
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
Drug Channels
This week, we’re rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .
Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied
KFF Medicare
Certain insurers must now publicly report specific prior authorization metrics, but the new data offer limited insight, providing no information on what types of services are being approved and denied
NHS to offer Wegovy to a million more people in England
Pharmaphorum
The NHS in England will make Novo Nordisk’s Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
UCB brings first therapy for rare disease TK2d to EU
Pharmaphorum
The EU has approved UCB’s Kygevvi for rare disease TK2d, and Sanofi’s acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments
Drug Channels
Three is still the magic number for pharmacy benefit managers (PBMs).